Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiogenXSWX:BIIB 73 3-Year Book Growth Rate is 10.20% as of Jun. 2026, which is 24% below its 10-year median of 13.40. GuruFocus rates XSWX:BIIB with a GF Score™ of 73/100 and a GF Value™ of CHF156.65. The stock has 10 warning signs investors should review. Among 913 Drug Manufacturers companies, Biogen ranks better than 70.54% on this metric.
During the past 12 months, Biogen's average Book Value per Share Growth Rate was 6.10% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 10.20% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 13.00% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 10.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Biogen was 105.70% per year. The lowest was -11.40% per year. And the median was 13.40% per year.
Biogen (XSWX:BIIB) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Biogen 3-Year Book Growth Rate Related Terms
XSWX:BIIB vs OGN, AMRN, NSRX: 3-Year Book Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Biogen's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogen 3-Year Book Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biogen's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Biogen's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 10.20% mean?
Biogen (XSWX:BIIB) has a 3-Year Book Growth Rate of 10.20% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Biogen and its competitors. This is 24% below median its historical median of 13.40. According to the industry distribution chart, Biogen ranks #269 out of 913 companies in the Drug Manufacturers industry, placing it in the top 29.5%.
Is Biogen's 3-Year Book Growth Rate too high?
Biogen's current 3-Year Book Growth Rate of 10.20% is 24% below median its 10-year median of 13.40. The Drug Manufacturers industry median 3-Year Book Growth Rate is 4.60. Biogen's value of 10.20% is 121.7% above this industry median. Based on the distribution chart, Biogen ranks #269 out of 913 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Biogen has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Biogen's 3-Year Book Growth Rate compare to OGN and AMRN?
According to the Drug Manufacturers industry distribution chart, Biogen ranks #269 out of 913 companies for 3-Year Book Growth Rate. This puts Biogen in the upper half of its industry. The industry median 3-Year Book Growth Rate is 4.60. Biogen's value of 10.20% is 121.7% above this benchmark. While the company's 10-year median is 13.40 vs. the industry median of 4.60, Biogen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.60, based on 913 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biogen's current 3-Year Book Growth Rate of 10.20% is 121.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Biogen and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogen's current 3-Year Book Growth Rate is 10.20%, which is 24% below median its own 10-year median of 13.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Biogen (XSWX:BIIB) has a current 3-Year Book Growth Rate of 10.20%. The stock's GF Value™ is CHF156.65, compared to a current price of CHF173.46 — trading 10.7% above its estimated fair value. The current 3-Year Book Growth Rate is 10.20%, which is 24% below median its 10-year median of 13.40 and 121.7% above the Drug Manufacturers industry median of 4.60. Biogen's overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Biogen (XSWX:BIIB), the current 3-Year Book Growth Rate is 10.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogen (XSWX:BIIB) Overvalued in 2026?
Based on GuruFocus' analysis, Biogen stock appears to be overvalued.
The current stock price of CHF173.46 is trading 10.7% above its estimated GF Value™ of CHF156.65.
Key valuation signals for XSWX:BIIB:
3-Year Book Growth Rate: 10.20% (24% below median its 10-year median of 13.40)
GF Value™: CHF156.65 vs. price of CHF173.46 (10.7% above fair value)
Industry Position: 121.7% above the Drug Manufacturers median (#269 of 913)
No single metric tells the full story. See the XSWX:BIIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
73GF Score
Get the complete analysis for XSWX:BIIB
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BIIB has been successfully added to your 
